Related Experiment Video
Updated: Feb 28, 2026
08:47
Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes
Published on: December 16, 2022
2.8K
GFR decline as an end point in trials of CKD: a viewpoint from the FDA
Aliza Thompson1, John Lawrence1, Norman Stockbridge1
1Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland.
Abstract
No abstract available in PubMed .
